Research is at the heart of innovative solutions to cancer.
Here are just a few Boilermaker researchers who have moved their research from lab to life with the help of the Purdue Innovates Office of Technology Commercialization:
Zhong-Yin Zhang
Current immunotherapy approaches are effective in only 15% of the patient population. Innovations like Zhang’s TC-PTP offer a novel alternative approach that degrades an enzyme found in cancer cells, alerting the immune system to the presence of tumor cells.
Yoon Yeo
Yeo’s nanoparticles slowly release drugs that induce immunogenic cell death, or ICD, in tumors. ICD results in a regulated activation of the immune response which is helpful since many cancer patients do not have powerful immune cells to fight tumors on their own.
Herman Sintim
Sandro Matosevic
Glioblastoma brain tumors are almost always lethal — with a median survival time of 14 months — since traditional methods used against other cancers are often ineffective. Matosevic is leading a team developing an immunotherapy based on novel, genetically engineered immune cells.
Phil Low
Media contact: Polly Barks, phbarks@prf.org
